<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179864</url>
  </required_header>
  <id_info>
    <org_study_id>EZH-1101</org_study_id>
    <nct_id>NCT04179864</nct_id>
  </id_info>
  <brief_title>Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy</brief_title>
  <official_title>A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epizyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epizyme, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1b/2 study to examine taz in combination with enz or abi/pred in patients with&#xD;
      metastic castration resistant prostate cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a global, multi-center, open-label, randomized phase 1b, active-controlled safety and&#xD;
      efficacy study of oral administration of tazemetostat in combination with enzalutamide or&#xD;
      abiraterone/prednisone (phase 1b) versus enzalutamide or abiraterone/prednisone alone in&#xD;
      asymptomatic or mildly symptomatic subjects with progressive, metastatic castration-resistant&#xD;
      prostate cancer (mCRPC) who have progressed on either abiraterone acetate, enzalutamide, or&#xD;
      apalutamide or who are second generation anti-androgen treatment naive, and who have not&#xD;
      received chemotherapy for mCRPC. This study is designed to determine the recommended phase 2&#xD;
      doses (RP2D) of tazemetostat in combination with either enzalutamide or&#xD;
      abiraterone/prednisone, based on safety, tolerability, pharmacokinetic, pharmacodynamic, and&#xD;
      efficacy profiles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ph 1b: Determine the safety and tolerability of each of the combinations</measure>
    <time_frame>Assessed at end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Assess safety and tolerability of Tazemetostat in combination with enzalutamide or with abiraterone/prednisone by reviewing incidence and severity of treatment-emergent adverse events (AEs) qualifying as protocol-defined DLTs in Cycle 1Safety and tolerability of Tazemetostat in combination with enzalutamide or with abiraterone/prednisone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ph 1b: Select the recommended phase 2 doses (RP2D) of tazemetostat for each combination</measure>
    <time_frame>1 cycle/28 days</time_frame>
    <description>Based on pharmacokinetic (PK) and pharmacodynamic parameters as well as efficacy and the overall tolerability of each of the combinations (tazemetost with enzalutamide or tazemetostat with abiraterone/prednisone)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ph 2: Determine the benefit of combining tazemetostat with enzalutamide when compared to enzalutamide alone by assessing change in radiographic progression free survival</measure>
    <time_frame>Day 1 of Cycles 3, 5, 7, 10, and 13, and every 12 weeks after Cycle 13 for 1 year (each cycle is 28 days)</time_frame>
    <description>Assessed by change radiographic progression free survival (rPFS) according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria for progression in bone or in soft tissue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine benefit of combining tazemetostat with enzalutamide or abiraterone/prednisone (phase 1b) and benefit of combining tazemetostat with enzalutamide when compared to enzalutamide alone (phase 2) - PSA Change</measure>
    <time_frame>Assessed at Day 1 of every cycle for an average of one year (each cycle is 28 days)</time_frame>
    <description>Confirmed prostate-specific antigen (PSA) responses will be defined as ≥50% reductions in PSA from baseline to lowest post baseline PSA result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine benefit of combining tazemetostat with enzalutamide or abiraterone/prednisone (phase 1b) and benefit of combining tazemetostat with enzalutamide when compared to enzalutamide alone (phase 2) - PSA Change</measure>
    <time_frame>Assessed at Day 1 of every cycle for an average of one year (each cycle is 28 days)</time_frame>
    <description>PSA progression is defined as a ≥25% increase from baseline to the day of PSA progression per PCWG3 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine benefit of combining tazemetostat with enzalutamide or abiraterone/prednisone (phase 1b) and benefit of combining tazemetostat with enzalutamide when compared to enzalutamide alone (phase 2) - First Skeletal-Related Event (SRE)</measure>
    <time_frame>During screening and every 9 weeks if clinically indicated at baseline, average of one year.</time_frame>
    <description>Time from randomization to first SRE will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine benefit of combining tazemetostat with enzalutamide or abiraterone/prednisone (phase 1b) and benefit of combining tazemetostat with enzalutamide when compared to enzalutamide alone (phase 2) - ORR</measure>
    <time_frame>Assessed at Day 1 of every cycle for an average of one year (each cycle is 28 days)</time_frame>
    <description>Assess objective response rate (ORR) per PCWG3 criteria and RECIST 1.1 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine benefit of combining tazemetostat with enzalutamide or abiraterone/prednisone (phase 1b) and benefit of combining tazemetostat with enzalutamide when compared to enzalutamide alone (phase 2) - DCR</measure>
    <time_frame>Assessed at 6 months on treatment</time_frame>
    <description>Assess disease control rate (DCR), no radiographic progression per PCWG3 criteria and no unequivocal clinical progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability of the combination of study drugs by assessing PK data</measure>
    <time_frame>Phase 1b PK of Tazemetostat will be assessed on Day 1 of Cycles 1 and 2. Phase 2 PK of Tazemetostat will be assessed on Day 1 of Cycles 2, 3, 5 and 10. (each cycle is 28 days)</time_frame>
    <description>Assess the PK of tazemetostat from collection of blood draws</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability of the combination of study drugs by assessing PK data</measure>
    <time_frame>Phase 1b PK of enzalutamide will be assessed on Day 1 of Cycles 1 and 2. Phase 2 PK enzalutamide will be assessed on Day 1 of Cycles 2, 3, 5 and 10. (each cycle is 28 days)</time_frame>
    <description>Assess the PK of enzalutamide from collection of blood draws</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability of the combination of study drugs by assessing PK data</measure>
    <time_frame>Phase 1b PK of abiraterone/prednisone will be assessed on Day 1 of Cycles 1 and 2. (each cycle is 28 days)</time_frame>
    <description>Assess the PK of abiraterone/prednisone from collection of blood draws</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the rate of reducing circulating tumor cells (CTC)</measure>
    <time_frame>Assessed at screening, on Day 1 of Cycles 1, 2, 3, 4, 5, 7, 10 and 13 (each cycle is 28 days) and post-treatment (30 days after last dose)</time_frame>
    <description>Assess the rate of reducing circulating tumor cells (CTC) from a state of having a detectable number of CTCs to having an undetectable number of CTCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess CTC response rate</measure>
    <time_frame>Assessed at screening, Day 1 of Cycles 1, 2, 3, 4, 5, 7, 10, 13 (each cycles is 28 days), and post-treatment (30 days after last dose)</time_frame>
    <description>Assess CTC response rate as defined by a ≥30% reduction in CTC number from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PHASE 2 ONLY: To determine the benefit of combining tazemetostat with enzalutamide when compared to enzalutamide alone, quality of life (QoL) will be assessed.</measure>
    <time_frame>Assessed at screening, Day 1 of Cycles 3, 5, 7, 10, 13 (each cycle is 28 days), and post-treatment (30 days after last dose)</time_frame>
    <description>Quality of Life (QoL) as assessed by changes from baseline in FACT-P Functional Well-being Subscale (FWB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PHASE 2 ONLY: To determine the benefit of combining tazemetostat with enzalutamide when compared to enzalutamide alone, quality of life (QoL) will be assessed.</measure>
    <time_frame>Assessed at screening, Day 1 of Cycles 3, 5, 7, 10, 13 (each cycle is 28 days), and post-treatment (30 days after last dose)</time_frame>
    <description>Quality of Life (QoL) as assessed by changes from baseline in Brief Pain Inventory (BPI) short form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PHASE 2 ONLY: To determine the benefit of combining tazemetostat with enzalutamide when compared to enzalutamide alone, quality of life (QoL) will be assessed.</measure>
    <time_frame>Assessed at screening, Day 1 of Cycles 3, 5, 7, 10, 13 (each cycle is 28 days), and post-treatment (30 days after last dose)</time_frame>
    <description>Quality of Life (QoL) as assessed by changes from baseline in EQ-5D-5L visual analogue scale.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1b: Tazemetostat in Combination with Abiraterone/Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 1b, Abiraterone/prednisone will be administered on cycle 1 day 1 and Tazemetostat on cycle 1 day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Tazemetostat in Combination with Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 1b, Enzalutamide will be administered on cycle 1 day 1 and Tazemetostat on cycle 1 day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Tazemetostat in Combination with Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 2, Enzalutamide and Tazemetostat will be administered on cycle 1 day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Enzalutamide only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Phase 2, Enzalutamide will be administered on cycle 1 day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene</description>
    <arm_group_label>Phase 1b: Tazemetostat in Combination with Abiraterone/Prednisone</arm_group_label>
    <arm_group_label>Phase 1b: Tazemetostat in Combination with Enzalutamide</arm_group_label>
    <arm_group_label>Phase 2: Tazemetostat in Combination with Enzalutamide</arm_group_label>
    <other_name>EPZ-6438</other_name>
    <other_name>E7438</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone/prednisone</intervention_name>
    <description>1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.</description>
    <arm_group_label>Phase 1b: Tazemetostat in Combination with Abiraterone/Prednisone</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>enzalutamide 160 mg (four 40 mg capsules) orally once daily</description>
    <arm_group_label>Phase 1b: Tazemetostat in Combination with Enzalutamide</arm_group_label>
    <arm_group_label>Phase 2: Enzalutamide only</arm_group_label>
    <arm_group_label>Phase 2: Tazemetostat in Combination with Enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age at the time of consent ≥ 18 years.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 (Appendix&#xD;
&#xD;
          3. Life expectancy of &gt; 3 months.&#xD;
&#xD;
          4. Histologically or cytologically confirmed adenocarcinoma of the prostate. Small cell&#xD;
             or neuroendocrine tumors of the prostate are also permitted.&#xD;
&#xD;
          5. Progressive disease in the setting of medical or surgical castration (ie, castration-&#xD;
             resistant prostate cancer [CRPC]) by PCWG3 criteria for study entry.&#xD;
&#xD;
               -  Evidence of disease progression by rising PSA or&#xD;
&#xD;
               -  Soft tissue progression per RECIST 1.1 or&#xD;
&#xD;
               -  Evidence of disease progression by observation of 2 new bone lesions since the&#xD;
                  initiation of last systemic therapy.&#xD;
&#xD;
          6. Metastatic prostate cancer disease, documented by the following imaging&#xD;
&#xD;
             • Bone lesions on bone scan (per PCWG3) or by soft tissue disease (per RECIST 1.1) by&#xD;
             CT/MRI imaging Must have undergone bilateral orchiectomy or be willing to continue&#xD;
             GnRH analogue or antagonist.&#xD;
&#xD;
          7. Prior treatment with a second-generation androgen inhibitor as follows:&#xD;
&#xD;
               -  For phase 1b, EITHER Previously untreated with or progressed on a second&#xD;
                  generation androgen inhibitor (abiraterone, enzalutamide, or apalutamide) OR&#xD;
                  progressed on a second generation inhibitor (inhibitor (abiraterone,&#xD;
                  enzalutamide, or apalutamide)&#xD;
&#xD;
               -  For phase 2 randomized component (i.e, enzalutamide- containing treatment arms)&#xD;
                  of the study, previously progressed on abiraterone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known symptomatic brain metastases&#xD;
&#xD;
          2. Treatment with any of the following for prostate cancer within the indicated timeframe&#xD;
             prior to day 1 of starting study treatment:&#xD;
&#xD;
               -  First generation: AR antagonists (eg, bicalutamide, nilutamide, flutamide) within&#xD;
                  4 weeks.&#xD;
&#xD;
               -  5-alpha-reductase inhibitors, ketoconazole, estrogens (including&#xD;
                  diethylstilbesterol), or progesterones within 2 weeks.&#xD;
&#xD;
               -  Chemotherapy (except as permitted in inclusion criteria #10) within 3 weeks.&#xD;
&#xD;
               -  Prior radionuclide therapy within 4 weeks.&#xD;
&#xD;
               -  Another interventional product or standard agent in a clinical study within 28&#xD;
                  days prior to the first planned dose of Tazemetostat&#xD;
&#xD;
               -  For phase 2 subjects to be randomized to one of the enzalutamide treatment arms&#xD;
                  only, prior treatment with the second-generation androgen inhibitor enzalutamide&#xD;
&#xD;
          3. Severe concurrent disease, infection, or comorbidity that, in the judgment of the&#xD;
             Investigator, would make the subject inappropriate for enrollment&#xD;
&#xD;
          4. Has had prior exposure to tazemetostat or other inhibitor(s) of enhancer of zeste&#xD;
             homologue-2.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shefali Agarwal, MD</last_name>
    <phone>617-229-7575</phone>
    <email>clinicaltrials@epizyme.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Powers, DO</last_name>
    <phone>978-289-8488</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Institute of Urology - Northwest</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>San Bernardino Urological Associates</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Genesis Healthcare Partners</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Dato, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paul Dato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Urology Center Of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Karsh</last_name>
    </contact>
    <investigator>
      <last_name>Lawrence Karsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of the Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Iannotti, MD</last_name>
      <phone>772-223-5982</phone>
    </contact>
    <investigator>
      <last_name>Nicholas Iannotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XCancer - University Cancer and Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petros Nikolinakos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Petros Nikolinakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XCancer - Northwest Oncology and Hematology</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruce Bank, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bruce Bank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - Broadway</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Taplin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mary Taplin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Einstein, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Einstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada - Central Valley</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Vogelzang, MD</last_name>
      <phone>702-953-3400</phone>
    </contact>
    <investigator>
      <last_name>Nicholas Vogelzang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Ferrari, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anna Ferrari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wassim Abida</last_name>
    </contact>
    <investigator>
      <last_name>Wassim Abida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of NY, PLLC - Urology</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Pieczonka, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christopher Pieczonka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Appleman, MD</last_name>
      <phone>412-648-6538</phone>
    </contact>
    <investigator>
      <last_name>Leonard Appleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI - Tennessee Oncology Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edward Arrowsmith, MD</last_name>
    </contact>
    <investigator>
      <last_name>Edward Arrowsmith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Associates P.C.</name>
      <address>
        <city>Hendersonville</city>
        <state>Tennessee</state>
        <zip>37075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Morris, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XCancer - Tennesee Cancer Specialists</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Lee, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI - Tennessee Oncology Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meredith McKean, MD</last_name>
    </contact>
    <investigator>
      <last_name>Meredith McKean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Saltzstein, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Saltzstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Groeninge Campus Kennedylaan</name>
      <address>
        <city>Kortrijk</city>
        <state>West Vlaanderen</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siska Van Bruwaene, MD</last_name>
    </contact>
    <investigator>
      <last_name>Siska Van Bruwaene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Jerez de la Frontera</name>
      <address>
        <city>Jerez De La Frontera</city>
        <state>Cadiz</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alvaro Juarez Soto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alvaro Juarez Soto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i. Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Pablo Maroto Rey, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jose Pablo Maroto Rey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar Parc de Salut Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejo Martin Rodriguez Vida Rodriguez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alejo Martin Rodriguez Vida Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Luis Gonzalez Larriba, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jose Luis Gonzalez Larriba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Ernesto Castellano Gauna, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Ernesto Castellano Gauna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alvaro Pinto Marin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alvaro Pinto Marin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Perez Garcia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jose Luis Perez Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic castration resistant prostate cancer</keyword>
  <keyword>tazemetostat</keyword>
  <keyword>EPZ-6438</keyword>
  <keyword>E7438</keyword>
  <keyword>enzalutamide</keyword>
  <keyword>abiraterone</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Zytiga</keyword>
  <keyword>Xtandi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

